Is GHK-Cu Legal?

The short answer (and why it is not quite enough)

GHK-Cu is a small copper-binding peptide that forms naturally in the human body and has a long track record as a topical cosmetic ingredient — legally, and with real clinical data behind it. As a cosmetic, it is permitted in the US, the EU, and the UK; the Cosmetic Ingredient Review concluded it was safe at typical use concentrations in 2018 ^[1]. As a drug, it has no FDA approval for any indication. As an injectable research chemical, it is experimental with no validated human pharmacokinetic data and a contested history on the FDA compounding bulks list ^[3].

The regulatory picture is unusually scattered: the cosmetic record, the drug record, the compounding record, and the athlete record all live in different documents from different agencies. This site reads those documents in one place, links to the live source next to each claim, and flags when a status is disputed or moving. For what people report and the safety cautions, there is a dedicated page. For the underlying research, see the research page.

The short answer, and why the short answer is misleading

GHK-Cu is legal in some forms and contexts, and not approved in others. That sentence does most of the work, but it hides where the actual fights are.

As a cosmetic ingredient, copper tripeptide-1 (the INCI name for GHK-Cu) is permitted in topical products in the United States, the European Union, and the United Kingdom. The Cosmetic Ingredient Review Expert Panel reviewed it in 2018 and concluded it was safe as used at typical concentrations of roughly 0.05 to 1 percent ^[1]. The EU lists it in the CosIng database under reference 55687, regulated by Regulation (EC) No. 1223/2009 ^[2]. The UK retained an essentially identical regime post-Brexit.

As a drug, GHK-Cu has no FDA approval for any human therapeutic indication. None. There is no New Drug Application that has cleared the bar, and the agency has historically scrutinized injectable forms on the Section 503A interim bulks list — at one point placing injectable GHK-Cu in Category 2 (significant safety risk) before, per a 2026 industry summary, removing it pending further Pharmacy Compounding Advisory Committee review ^[3]. Topical compounded GHK-Cu has generally been treated as Category 1 (no enforcement intent), but the rules here move and the live FDA bulks list should be checked directly before any commercial reliance.

As a research chemical, GHK-Cu is sold with non-human-use labeling — a regulatory boundary, not an endorsement of human use. The research-chemical designation governs labeling requirements, not the underlying biology.

The rest of this site is the long version of that paragraph, with the source documents linked next to each claim.

What the molecule actually is

GHK-Cu is the copper(II) complex of a small natural tripeptide — glycyl-L-histidyl-L-lysine, three amino acids end to end, chelated to a single Cu(II) ion. Its CAS number for the free peptide is 49557-75-7 and its PubChem CID is 73587. The free peptide is 340.38 daltons; the copper is held by the imidazole nitrogen of histidine, the alpha-amino nitrogen of glycine, and the deprotonated amide nitrogen of the glycine-histidine bond ^[4].

It is not exotic. GHK was first isolated from human albumin by Loren Pickart in 1973, and it circulates in human plasma at roughly 200 nanograms per milliliter at age 20, declining to about 80 ng/mL by age 60 ^[4]. A small, declining endogenous peptide is what most of the literature is in conversation with — the question is whether topical, injected, or compounded preparations meaningfully raise local or systemic concentrations enough to produce the effects seen in cell culture and rodent models.

That distinction — endogenous and quiet versus exogenous and dosed — is also why the regulatory categories split the way they do. A cosmetic that puts a tiny amount of copper tripeptide-1 on the skin is a different object, legally and pharmacologically, from a compounded injectable purporting to act systemically.

Where the four big regulatory questions actually land

Search demand for this compound concentrates around four questions. Each gets a full treatment on its own page; this is the index card.

Is GHK-Cu FDA-approved? No — not as a drug, for any indication. As a cosmetic ingredient it is regulated under the FD&C Act and the Modernization of Cosmetics Regulation Act (MoCRA), which does not pre-approve cosmetic ingredients but does require manufacturers to substantiate ingredient safety ^[5]. The 2018 CIR review is the standing US safety reference ^[1].

Is injectable GHK-Cu legal? It is sold as a research chemical with non-human-consumption labeling. Compounding pharmacies operating under Section 503A have historically been able to prepare topical GHK-Cu; injectable forms have been treated more cautiously by the FDA and the bulks-list status has moved more than once. Confirm directly at fda.gov before relying on any specific status ^[3].

Is GHK-Cu banned by WADA? It is not explicitly named on the current World Anti-Doping Agency Prohibited List. WADA's categories use broad 'similar substances' language, however, and athletes should consult the most recent edition in force and their national anti-doping authority before any use ^[6].

Is GHK-Cu legal in cosmetics? Yes — broadly. The US permits it under MoCRA, the EU permits it under CosIng entry 55687, and the UK retains the EU framework. Each finished product still needs a Cosmetic Product Safety Report and a Responsible Person on the EU market, and any product marketed in the US must comply with MoCRA's facility registration and product listing requirements ^[2][5].

The page also matters: a cosmetic GHK-Cu cream that promises to 'improve the appearance of fine lines' is regulated as a cosmetic; the same cream that promises to 'heal wounds' or 'reverse aging' has, in the FDA's reading, transformed itself into an unapproved drug. The molecule has not changed. The marketing claims have.

What this site is, and is not

GHK-Cu Legal is an independent editorial project that publishes reading notes on the regulatory status of GHK-Cu. The editors read the primary documents — FDA bulks list memos, the CIR 2018 final report, the EU CosIng entry, the WADA Prohibited List, the Federal Register filings on compounding — and write plain-language summaries with the live source URL next to each claim. Every regulatory callout on the site carries a small mono chip showing the date the claim was verified and a circular badge linking to the source document itself.

We are not a law firm. We do not employ attorneys, regulatory affairs specialists, or compliance consultants. We do not sell any product and are not affiliated with any cosmetic manufacturer, compounding pharmacy, research-chemical vendor, or longevity clinic. Nothing on this site is legal advice, medical advice, or regulatory guidance. For decisions that affect your business, your competition, or your health, consult a licensed attorney, a regulatory specialist, or a physician.

For the long versions, the research page walks through the published GHK-Cu literature; dosage summarizes what concentrations and routes have actually been studied; the FAQ hits the ten most-asked questions head-on; and references is the complete citation index, with every primary regulator source linked.